Patents Assigned to Universitat zu Luebeck
  • Antisense drugs against canine ICAM-1 for use in the treatment of inflammation of the buccal cavity
    Patent number: 11773394
    Abstract: The present invention relates to an isolated antisense oligonucleotide for use in a method of preventing or treating an inflammatory disease or condition of the buccal cavity in a canine subject, wherein said antisense oligonucleotide is directed against canine ICAM-1. The present invention further relates to compositions or articles of manufacture comprising said antisense oligonucleotide.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: October 3, 2023
    Assignee: Universität zu Lübeck
    Inventors: Georg Sczakiel, Rosel Kretschmer-Kazemi Far, Franziska Preuss
  • Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1)
    Publication number: 20220106601
    Abstract: The present invention relates to a specific antisense oligonucleotide which inhibits the expression of the adhesion molecule ICAM-1 in human cells. The present invention further relates to a vector containing said oligonucleotide and a host cell containing said vector or oligonucleotide and a pharmaceutical composition containing said oligonucleotide as well as uses thereof, in particular in the treatment of an inflammatory disease or condition in humans.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 7, 2022
    Applicant: Universität Zu Lübeck
    Inventors: Georg Sczakiel, Rosel Kretschmer-Kazemi Far
  • ANTISENSE DRUGS AGAINST CANINE ICAM-1 FOR USE IN THE TREATMENT OF INFLAMMATION OF THE BUCCAL CAVITY
    Publication number: 20210310009
    Abstract: The present invention relates to an isolated antisense oligonucleotide for use in a method of preventing or treating an inflammatory disease or condition of the buccal cavity in a canine subject, wherein said antisense oligonucleotide is directed against canine ICAM-1. The present invention further relates to compositions or articles of manufacture comprising said antisense oligonucleotide.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 7, 2021
    Applicant: UNIVERSITÄT ZU LÜBECK
    Inventors: Georg SCZAKIEL, Rosel KRETSCHMER-KAZEMI FAR, Franziska PREUSS
  • Antisense drugs against canine ICAM-1 for use in the treatment of inflammation of the buccal cavity
    Patent number: 11008574
    Abstract: The present invention relates to an isolated antisense oligonucleotide for use in a method of preventing or treating an inflammatory disease or condition of the buccal cavity in a canine subject, wherein said antisense oligonucleotide is directed against canine ICAM-1. The present invention further relates to compositions or articles of manufacture comprising said antisense oligonucleotide.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: May 18, 2021
    Assignee: Universität zu Lübeck
    Inventors: Georg Sczakiel, Rosel Kretschmer-Kazemi Far, Franziska Preuss
  • Crystal structure of human coronavirus 229E main proteinase and uses for developing SARS inhibitors
    Patent number: 7956078
    Abstract: The invention relates to a method of developing a main proteinase SARS inhibitor. Human coronaviruses are major causes of upper respiratory tract illnesses in humans, in particular, the common cold. Recent investigations have shown that a novel coronavirus causes the Severe Acute Respiratory Syndrome (SARS), a disease that is characterized by high fever, malaise, rigor, headache, non-productive cough or dyspnea, which is rapidly spreading. Within the scope of the invention, based on the structural analysis of the binding mode of the SARS Mpro enzyme, a group of prototype inhibitors is provided that acts as suitable drugs targeting a majority of viral infections of the respiratory tract, including SARS.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 7, 2011
    Assignee: Universitat zu Luebeck
    Inventors: Rolf Hilgenfeld, Kanchan Anand, John Ziebuhr, Jeroen R. Mesters, Parvesh Wadhwani